Gastroesophageal reflux disease (GERD) is a common disease and a considerable burden on healthcare resources. Definitions and terminology have been a source of confusion for GERD. The 'Montreal definition' is the first ever global consensus definition of GERD. The esophageal and extraesophageal syndromes are now considered the two constituent syndromes of GERD. The pathogenesis of gastroesophageal reflux is multi-factorial and a failure of the anti-reflux barrier allowing the stomach content to enter the esophagus is the target of interest. Heartburn and acid regurgitation are the typical symptoms of the disease, although some patients may have atypical manifestations of GERD. The long term complication of GERD includes esophageal stricture, Barrett's esophagus with consequent increase in the risk of esophageal adenocarcinoma. Diagnosis of GERD can usually be established on the basis of a careful history and physical examination. Detailed diagnostic studies are not necessary in a patient presenting with typical symptoms with no alarming features. Patients with alarming feature in addition to their GERD symptoms require prompt investigation and usually endoscopy is preferred. Treatment of GERD is directed at acid suppression through the use of lifestyle modifications and pharmacologic agents from over-the-counter (OTC) agents ranging from antacids to proton pump inhibitors (PPIs). New algorithm of treatment of GERD has also been proposed. Antireflux surgery, including open and laparoscopic, and newer endoscopic procedures are alternative modalities of treatment in case of failure of medical therapy.
Gastroesophageal reflux disease (GERD)
Gastroesophageal reflux disease (GERD) is a common medical problem with a broad spectrum of symptoms and varying degrees of severity 1 . The modern concept of reflux esophagitis dates back to 1935 when a landmark article in JAMA first suggested gastric secretions may cause the mucosal damage 2 . Later in 1946 Allison identified the fundamental pathophysiological process and introduced the term 'reflux esophagitis' 3 .
Definition and Classification of GERD
The first ever global consensus definition of gastroesophageal reflux disease (GERD) is known as Montreal definition which defines the condition as "a condition which develops when the reflux of stomach contents causes troublesome symptoms and/or complications" 4 .
The patients having GERD is broadly classified into two groups on the basis of endoscopy findings-having esophageal mucosal damage (erosive esophagitis and Barrett's esophagus) and no mucosal damage (endoscopy-negative reflux disease, symptomatic GERD, or non erosive reflux disease) (Box 1) 5 .
Heartburn and acid regurgitation are the archetypal symptoms of GERD and most patients with typical symptom of GERD can be treated empirically. Hence the term 'heartburn dominant undiagnosed dyspepsia' was coined to denote the group who have symptoms, referable to the esophagus or reduced quality of life attributable to gastroesophageal reflux, in the absence of any prior investigations 6 .
The Montreal definition did not use the term 'nonerosive reflux disease' but rather classified GERD into esophageal and extraesophageal syndromes. Esophageal GERD syndromes are categorized as those that are symptoms and other with esophageal injury while the extraesophageal syndromes are classified as of established or proposed association with GERD, acknowledging that while the evidence on hand is sufficient to link these syndromes to reflux, it is insufficient to establish causation 4 .
Epidemiology
Symptoms of GERD found to be very common, affecting up to 20% of the population in North America, 9% to 17% in Europe, 12% to 15% in Australia, and 2% to 5% in Asia once a week 7 . The study by El GERD is found to be equally prevalent among men and women. However, female preponderance (2:1 to 3:1) was observed in case of esophagitis and male in (10:1) Barrett's metaplasia 12 . Pregnancy is associated with the highest incidence of GERD with 48% to 79% of pregnant women complaining of heartburn 13 . The role of genetic factors was suggested by twin studies wherein heritability accounted for 31%-43% of the likelihood of reflux disease, which suggests both genetic and environmental factors play an important role in is pathogenesis 14, 15 . Regarding environmental factors there is sufficient evidence to support the relationship between being obese or overweight and GERD 16 . Among others factors dietary habits, the lack of physical activity and smoking frequently linked to be the risk factors for GERD. However, the exact pathogenic role of these factors is still debated 17, 18 .
Pathogenesis of GERD
Schematically, the esophagus, lower esophageal sphincter (LES), and stomach can be envisioned as a simple plumbing circuit. The esophagus functions as an antegrade pump, the LES as a valve, and the stomach as a reservoir. The abnormalities that contribute to GERD can stem from any component of the system 19 .
Esophageal Syndrome
The factors generally accepted as important for the development of gastroesophageal reflux disease (GERD) have been well documented (Box 2) [20] [21] [22] . Despite the many factors that operate, four main fundamental factors stand out as most important: (1) gastric acid; (2) the structural integrity, function, and competence of the LES that either prevent or allow reflux; (3) the esophageal mucosal defense mechanisms that are primarily called into play when there is excess exposure of the mucosa to gastric acid; and (4) the sensory mechanisms that speak to symptoms 23 .
A postprandial pocket of acid just below the gastro-esophageal junction has recently been described, and in patients with reflux, this acid pocket shows greater proximal extension, and is longer ( Figure 1 ). As this acid pocket can persist for up to 2 hour postprandially and remains highly acidic compared with the body of the stomach, it is likely that gastric buffering from a meal creates a non-uniform environment with at least two acid layers; the lack of homogeneity of the stomach contents may explain persistent acidic gastro-esophageal reflux after a meal 24 . 
Clinical presentation
The most common symptoms of GERD include heartburn or pyrosis, regurgitation, and dysphagia. Heartburn, defined as a burning sensation in the retrosternal area, has a specificity of 89% and positive predictive value of 81% for GERD. Regurgitation, defined as the sensation of gastric refluxate into the mouth or hypopharynx, has a specificity of 95% and positive predictive value of 57% for GERD. The combination of heartburn and regurgitation has an accuracy of greater than 90% for the diagnosis of GERD 25 . Increasing information is being gained through recent evidence regarding the "extraesophageal" presentations of this disease. These patients frequently do not complain of associated heartburn and regurgitation, leading to another synonym for this syndrome-the "atypical" presentations of GERD 26 . As many as 80% of patients with GERD may have at least one extraesophageal symptom 24 . The common atypical symptoms are asthma like symptom, chest pain, cough, laryngitis and sinusitis ( Table 2) .
Complications of GERD

Strictures
Peptic strictures represent severe end stages of reflux disease. Not only do peptic strictures develop in 4% to 20% of patients with reflux esophagitis, but as many as 25% to 50% of stricture cases have a concomitant columnar metaplasia of the squamous epithelium (Barrett's esophagus) 22 .
Barrett Esophagus (BE)
The most serious histologic consequence of GERD is Barrett's metaplasia. As a consequence of clinical and epidemiological evidence supporting the association between BE and esophageal adenocarcinoma.
BE is considered a precancerous lesion and accurate diagnosis of BE is crucial [28] [29] [30] . Patients with long-standing reflux symptoms are at risk for Barrett's esophagus. Microscopically, Barrett's is characterized by replacement of the normal squamous epithelium of the esophagus with a specialized columnar epithelium, known as intestinal metaplasia 25 . On endoscopic examination morphologically BE is a tongue-like extension of salmoncolored mucosa from the gastroesophageal junction 31 . Prevalence of BE in Western countries found to be varied from 6.3-13.6% in patients with GERD 32 . 33 .
Hemorrhage
Natural history of GERD
Most GERD patients do not seek medical attention and usually self-medicated. Two potential paradigms for the natural history of GERD exist. GERD is generally viewed as a progressive disease such that, in the absence of effective intervention, patient with nonerosive disease becomes tomorrow's patient with erosive disease and would become a candidate for the development of Barrett's esophagus. This "spectrum of disease" approach has been contrasted with the view that GERD may be a disease with phenotypically discreet "categories," such as nonerosive disease, erosive esophagitis, and Barrett's esophagus. In this view, conversion from one disease manifestation to another is distinctly unusual, and subjects generally stay in their initial category. Available, albeit limited, data suggest that while subjects with GERD may sometimes progress from nonerosive disease to erosive esophagitis (making it not a strictly categorical disease), the reported rates of progression are relatively low over a 20-year period. In patients in whom stricture, Barrett's metaplasia, and adenocarcinoma were excluded in the setting of a healed mucosa at index endoscopy, the likelihood of these developing within a 7-year followup period is on the order of 1.9%, 0.0%, and 0.1%, respectively 34 .
Differential diagnosis
Symptoms associated with GERD may be mimicked by coronary artery disease, gallbladder disease, gastric or esophageal malignancy, peptic ulcer disease, and eosinophilic, infectious, or caustic esophagitis, atypical cases of achalasia, distal esophageal spasm or functional heartburn 34, 35 .
Diagnosis of GERD
It is neither practical nor necessary to embark on a diagnostic evaluation of every patient who experience only heartburn. The primary goal of therapy is symptomatic relief. A diagnostic test for esophageal GERD syndromes is invoked in 3 broad scenarios: (1) avert misdiagnosis; (2) identify complications of reflux disease; and (3) evaluation of empirical treatment failures 34 .
Symptom-based diagnosis of GERD
The Montreal definition recognizes that GERD can be diagnosed in primary care on the basis of symptoms alone without additional diagnostic testing 4, 36, 37 . A welltaken history is essential in establishing the diagnosis of GERD. Symptoms of classic burning in the chest, with sour or bitter taste, and acid regurgitation have been shown to correctly identify GERD with a sensitivity of 89% and specificity of 94%. However, symptom frequency, duration and severity are equally distributed among patients with varying grades of esophagitis and Barrett's esophagus and cannot be used reliably to diagnose complications of GERD 38 . . Esophagitis is best defined by the LA classification system and identifies the degree to which mucosal breaks (erosions or ulcerations) occur, graded in severity from A to D, with D being the most severe 41 . Biopsy is indicated in defining Barrett's esophagus 41 .
Empiric/therapeutic trial
Ambulatory PH monitoring
Although no gold standard test exists for the diagnosis of GERD, ambulatory pH monitoring is accepted as the standard with a sensitivity of 85% and specificity of 95%
38
. Patients with endoscopic-negative GERD and who do not respond to medications are best evaluated by ambulatory pH monitoring. The purpose for pH probe must be defined before proceeding: is it to diagnose GERD or to determine the adequacy of therapy. The test should be performed off therapy if the diagnosis is under question. The test should be performed on therapy if one is trying to determine the adequacy of treatment. Recent advances in "wireless" pH radiotelemetry capsule eliminate the need for the uncomfortable nasoesophageal tube, and increases diagnostic yield by allowing for longer monitoring. Ambulatory pH monitoring is based upon the amount of time the intraesophageal pH is less than 4, with normal defined as less than 4% over a 24-hour period 34, 38 .
Other diagnostic modalities
Esophageal manometry can be used to evaluate patients with a suspected esophageal GERD syndrome who have not responded to an empirical trial of twicedaily PPI therapy and have normal findings on endoscopy. Manometry will serve to localize the lower esophageal sphincter for potential subsequent pH monitoring, to evaluate peristaltic function preoperatively, and to diagnose subtle presentations of the major motor disorders. Evolving information suggests that high-resolution manometry has superior sensitivity to conventional manometry in recognizing atypical cases of achalasia and distal esophageal spasm 34, 40 .
Esophageal capsule endoscopy in patients with suspected GERD and other esophageal disorders is feasible and safe, and could be also an alternative procedure in those patients refusing upper endoscopy 42 . • GERD symptoms that could be cardiac in origin.
Alarm Features for GERD
• Respiratory symptoms secondary to reflux
Box 3: Indications for endoscopy and further investigations
Treatment of GERD
Lifestyle modifications
Based on expert opinion, lifestyle modifications should be initiated and continued throughout the course of therapy in patients with a history of typical uncomplicated GERD 43 . Weight loss should be advised for overweight or obese patients with esophageal GERD syndromes and elevation of the head of the bed for patients who are troubled with heartburn or regurgitation when recumbent. Other lifestyle modifications including, but not limited to, avoiding late meals, avoiding specific foods, or avoidance of specific activities should be tailored to the circumstances of the individual cases 34, 38 . Although there is little supporting evidence, it is considered reasonable to educate patients about various factors that may precipitate reflux 44 .
Antacids and alginates
These acid suppressants are appropriate, initial patient-directed therapy for GERD. Antacids and combined antacid/alginic acid have been shown to be more effective than placebo in the relief of daytime GERD symptoms. 34, 38, 40 .
Antisecretory Therapies
Anti-secretory drugs are recommended strongly for the treatment of patients with esophageal GERD syndromes (healing esophagitis and symptomatic relief). A short course or as-needed use of antisecretory drugs should be used in patients with a symptomatic esophageal syndrome without esophagitis when symptom control is the primary objective. For a short course of therapy, PPIs are more effective than H2RAs, which are more effective than placebo 34, 45 . Twicedaily PPI therapy is recommended for patients with an esophageal syndrome with an inadequate symptom response to oncedaily PPI therapy. The most common side effects of PPIs are headache, diarrhea, constipation, and abdominal pain. Switching among alternative PPI drugs or to a lower dose can usually circumvent these side effects. As for the issue of onset of action, this primarily pertains to ondemand therapy. If a patient intends to take a drug only in response to symptoms, then it should be a rapidly acting drug. The most rapidly acting agents are antacids, the efficacy of which can be sustained by combining them with an H2RA or a PPI 34 .
Prokinetic or promotility agents
Drugs such as cisapride, metoclopramide and domperidone have been tried in the treatment of GERD. These agents have been proposed to increase peristalsis and LES tone. Cisapride is the only prokinetic agent that has shown clinical efficacy 46 ; however, it is no longer available on the market due to concerns about prolongation of QT interval, ventricular tachycardia and death. Due to the paucity of clinically
• Avoid large meals • Avoid acidic foods (citrus-and tomato-based products), alcohol, caffeinated beverages, chocolate, onions, garlic, and peppermint • Decrease dietary fat intake • Avoid lying down within three to four hours after a meal • Avoid medications that may potentiate GERD symptoms, including calcium channel blockers, beta agonists, alpha-adrenergic agonists, theophylline, nitrates, and some sedatives • Elevate the head of the bed 10 to 20 cm (4 to 8 inches)
• Avoid wearing clothing that is tight around the waist • Lose weight • Stop smoking relevant data, these agents are not recommended alone or in combination with anti-secretory agents for the long-term maintenance treatment of GERD 6, 47, 48 .
Treatment of patients with extraesophageal GERD Syndrome Twice-daily PPI therapy is recommended as an empirical trial for patients with suspected reflux chest pain syndrome after a cardiac etiology has been carefully considered. Acute or maintenance therapy with once-or twice-daily PPIs (or H2RAs) is recommended for patients with a suspected extraesophageal GERD syndrome (laryngitis, asthma) with a concomitant esophageal GERD syndrome 34 .
Maintenance treatment in GERD 38
The goal of maintenance therapy is to have a symptom free individual with no esophagitis. Chronic acid suppression will be required for adequate symptom control in the majority of subjects with GERD symptoms severe enough to warrant initial PPI therapy. While many subjects may tolerate dose reduction of their PPI and maintain adequate symptom control, the likelihood of long-term spontaneous remission of disease is low. Beyond recurrence of symptoms and/or erosive disease, the risks associated with cessation of therapy, including the possible development of Barrett's esophagus, appear minimal.
Options in maintenance regimens include: step-up therapy (starting less potent agents and moving up for treatment response), step-down therapy (using potent acid suppression initially with decreasing dose or less potent agents to tailor to the individuals response), on demand (patientdirected) therapy, or surgery, All options have the goal of complete symptom relief.
Step-up therapy: When beginning step-up therapy, no more than 2 weeks is needed to determine if a dosage of medication will be effective. Step-down therapy: Once symptoms are controlled after step-up therapy, step-down therapy commences with the patient taking a PPI for 8 weeks, followed by an H2RA if GERD symptoms were adequately controlled with a PPI, then stepping down further to on-demand use of antacids if the patient was asymptomatic while taking an H2RA. The majority of patients who take more than a single daily dose of a PPI and who experience relief of symptoms can be successfully stepped down to single-dose therapy without a recurrence of reflux symptoms. However, a small percentage of patients with refractory GERD will need long-term therapy with higher doses of a PPI to control symptoms.
On demand therapy
Treatment can be initiated with standard dosage of either a PPI daily or an H2RA twice daily on demand (patient directed therapy). Drug selection depends on clinical presentation, cost-effectiveness, and end point of appropriate symptom relief.
Role of Surgical treatment
Consideration of antireflux surgery must be individualized 43 . Patients who are well maintained on medical therapy have more to lose than to gain and should not be offered surgery 49 . Surgery may be recommended 6, 34 in the following situations:
1. When a patient with an esophageal GERD syndrome is responsive to, but intolerant of, acid suppressive therapy, or 2. has persistent troublesome symptoms, especially troublesome regurgitation, despite PPI therapy 3. Poor compliance (for example, due to medication costs) 4. Presence of a large hiatus hernia
The potential benefits of antireflux surgery should be weighed against the deleterious effect of new symptoms consequent from surgery, particularly dysphagia, flatulence, an inability to belch, and post surgery bowel symptoms 34 .
Newer endoscopic treatments
The endoluminal treatment of GERD is evolving and may have the potential to decrease the need for long-term antisecretory medications in selected patients 34 . A variety of endoscopic techniques for the treatment of GERD are currently available, including the delivery of radiofrequency energy to the gastroesophageal junction and suture plication of the proximal fundic folds, but there are no longer any devices that require injection of bulking agents or implantation of a bioprosthesis into the LES zone. Most studies of endoscopic therapy have only limited follow-up information, and data suggest that some of these techniques, in their current position, are not durable 50 .
Frequently reported complications for endoscopic treatments, intraoperatively or within 30 days after the procedure, included chest or retrosternal pain, gastrointestinal injury, bleeding, and shortterm dysphagia 51 .
Updated Treatment Algorithm
An updated treatment algorithm for the management of reflux disorders was suggested by an expert panel in 2006 (Table 3 ). This algorithm can be followed by patients and pharmacists when choosing OTC medications, PCPs and gastroenterologists in a secondary care setting 24 .
The algorithm is separated into three distinct therapeutic levels (self-care, primary care, and secondary care), with clear recommendations being provided at each level of care. A careful history and physical evaluation is essential, and consideration given as to whether the symptoms warrant an alternative diagnosis. Any alarm symptoms should be immediately referred for specialist investigation 24 .
Prospective pharmacotherapeutic agents for GERD 52 
New proton pump inhibitor isomers
Isomers of proton pump inhibitors e.g. Sisomer of omeprazole. S-pantoprazole and dexrabeprazole, are new isomers that offer therapeutic advantages as compared to racemic pantoprazole and racemic rabeprazole respectively.
New proton pump inhibitors
Tenaprazole (Tu-199) is a novel chemical compound which also belongs to the proton pump inhibitor class. Unlike other PPIs, tenaprazole is characterized by substantially prolonged half-life (7 hours).
Potassium competitive acid blockers
Potassium-competitive acid blockers (PCABs) represent a new class of drugs acting through a reversible binding mechanism different from the PPIs. In pharmacological studies, they have shown a fast onset of action (within 30 minutes of drug administration) with a maximum effect obtained after the first dose, whereas classical PPIs needs several days to reach their steady-state effect. 
